Targeted therapy is an emerging treatment option for various types of cancer, not only because of its efficacy, but also because of its preferential effect on cancer cells. Moreover, it is generally better tolerated by patients than other therapies (*i.e.*, chemotherapy) ([@B1]). One of the main disadvantages, similar to other options, however, is the development of tumor cell resistance appearing soon after beginning the treatment; therefore, combinations of two or more compounds are often desirable ([@B2]).

Proteasome inhibitors are a group of compounds that have become frequently used in cancer therapy ([@B3]). The 26S mammalian proteasome is a multiprotein enzymatic complex composed of the 20S core particle and two 19S regulatory particles ([@B4]). It is the final player in the ubiquitin--proteasome pathway, resulting in degradation of proteins. The proteasome recognizes proteins marked with ubiquitin for degradation, and thus regulates the strictly controlled cell protein balance under normal conditions. The 20S subunit contains three different enzymatic domains exerting specific catalytic activities---chymotrypsin-like, trypsin-like, and caspase-like---which are the primary targets for proteasome inhibitors ([@B3]).

The first-in-class proteasome inhibitor that was approved by the Food and Drug Administration is bortezomib (Velcade). It reversibly binds to threonine residues in the active site of the chymotrypsin-like catalytic region of the 20S subunit and thus inhibits its function ([@B5]). In initial studies, bortezomib showed efficacy in the treatment of various types of cancer, including multiple myeloma, mantle cell lymphoma, prostate, colon, and pancreatic cancer ([@B5]). It activates several signaling pathways leading to cell death, including apoptosis and autophagy, and it is also known to block the nuclear factor-*κ*B (NF-*κ*B) pathway, thus sensitizing cancer cells to chemotherapy and increasing their susceptibility to apoptotic cell death ([@B5], [@B6]). Bortezomib has also proven to be effective in combination with other proteasome inhibitors, chemotherapeutical agents, or radiation therapy ([@B3], [@B7]). Following the success of bortezomib in antitumor therapies, second-generation proteasome inhibitors, including carfilzomib, ixazomib, delanzomib, oprosomib, and salinosporamid A, were developed, also exhibiting promising results ([@B8], [@B9]).

Salinosporamid A (NPI-0052, marizomib) is a proteasome inhibitor originally isolated from the marine organism *Salinospora tropica* ([@B10]). It has been shown to be effective at inducing cell death in several cancer cell lines *in vitro* and *in vivo*, either as a single treatment or in combination with other compounds ([@B10]). It has been very frequently compared with bortezomib, with some studies showing that salinosporamid A was more effective and exhibited less side effects ([@B8]). Unlike bortezomib, salinosporamid A binds irreversibly to the active sites of all three catalytic regions of the 20S subunit ([@B10]). Salinosporamid A has been tested, either alone or in combination, in clinical trials for several cancers, including relapsed or refractory multiple myeloma and malignant glioma ([@B11], [@B12]).

Pheochromocytomas/Paragangliomas (PHEOs/PGLs) are rare neuroendocrine tumors that lack curative therapy for metastatic disease. The only effective treatment other than surgery is a combination of cyclophosphamide, vincristine, and dacarbazine (CVD); however, resistance is acquired in most patients ([@B13]). Like in other types of cancer, several compounds have been tested in PHEO/PGL in the search for effective treatment ([@B14]), including topoisomerase ([@B15]), mTOR pathway ([@B16]), heat-shock protein 90 ([@B17]), and tyrosine kinase ([@B18]) inhibitors. The results obtained with these drugs *in vitro* and in animal models showed rationale for testing them in clinical trials for PHEO/PGL.

In the present work, we studied the effects of bortezomib and salinosporamid A independently and in combination on two established PHEO cell lines, mouse pheochromocytoma cells (MPC) and mouse tumor tissue (MTT) cells ([@B14]). We found that both compounds are effective in these cells, although salinosporamid A is less effective in individual treatment both *in vitro* and *in vivo*. Both drugs exert their activity on the cells via induction of apoptosis and inhibition of migration and invasion *in vitro*, and bortezomib and the combination delayed tumor growth in animal models. Moreover, in *in vivo* studies, tumor growth inhibition with a combination of both drugs at lower doses was comparable to bortezomib alone at a higher dose. The combination also showed an additive inhibitory effect on PHEO cell proliferation, migration, invasion, and apoptosis induction *in vitro* and *in vivo*. In conclusion, we propose that bortezomib is a potential candidate for treatment of PHEO/PGL, especially as a part of a combination therapy. Furthermore, addition of salinosporamid A might allow to reduce bortezomib doses, possibly resulting in fewer side effects and a lower risk of resistance development.

Materials and Methods {#s1}
=====================

Cell lines and reagents {#s2}
-----------------------

The mouse pheochromocytoma cell lines MPC, MTT, and MTT-Luc ([@B19]) were maintained in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum, 5% horse serum, and antibiotic/antimycotic (Life Technologies, Carlsbad, CA). Bortezomib was purchased from Selleckchem (Houston, TX), and salinosporamid A from Adipogen (San Diego, CA); stock solutions were stored at −20°C and thawed prior to use.

Cell viability assay {#s3}
--------------------

Cell viability was assessed by the ability of cells to metabolize methylthiazolyldiphenyl-tetrazolium bromide (Sigma-Aldrich, St. Louis, MO), according to the manufacturer's instructions. Cells were seeded onto 96-well plates (Corning Inc., Corning, NY) at 1.0 × 10^4^ cells/well and maintained at 37°C overnight prior to the initiation of experimental treatments. The cells were treated with 0, 1, 10, 100, and 1000 nM bortezomib or salinosporamid A for 48 hours; in combination treatments, 10 nM salinosporamid A was combined with 1, 10, 100, and 1000 nM bortezomib. Following the indicated treatments, 10 μL methylthiazolyldiphenyl-tetrazolium bromide solution at 5 mg/mL was added to each well, and the cells were maintained in growth medium for 3 hours at 37°C. The cells were lysed, and absorbance at 490 nm was subsequently measured using a spectrophotometer (Omega Scientific, Offenburg, Germany). Untreated cells were used as controls. Cell viability was calculated as a percentage compared with untreated controls, and LD~50~, the dose leading to the death of 50% of the cells, was determined.

Cell migration and invasion assay {#s4}
---------------------------------

For the migration assay, an MPC suspension was prepared at a concentration of 0.5 × 10^6^ cells/mL in serum-free medium with or without tested drug. A total of 300 µL suspension was added to Transwell chambers with 8-µm pores (BD Biosciences, San Diego, CA), which were placed in 24-well plates with 500 µL complete medium per well, with or without tested drug. The treatments were as follows: 1 nM bortezomib, 10 nM salinosporamid A, and the combination of 1 nM bortezomib with 10 nM salinosporamid A. The cells were allowed to migrate for 24 hours. At the end of the experiment, nonmigrated cells from the upper parts of the chambers were removed with cotton swabs, and migrated cells were fixed in methanol and stained with 4′,6-diamidino-2-phenylindole (Life Technologies). The number of migrated cells was assessed using fluorescence microscope and analyzed with ImageJ software (National Institutes of Health, Bethesda, MD). The invasion assay was performed the same way using matrigel-coated Transwell chambers (Corning Inc.).

Western blotting {#s5}
----------------

The cells were washed twice with ice-cold phosphate-buffered saline and lysed in radioimmunoprecipitation assay buffer (Cell Signaling Technology, Danvers, MA) supplemented with Complete protease inhibitor cocktail (Roche, Basel, Switzerland) and phosphatase inhibitor cocktail (Cell Signaling Technology). Protein lysates were denatured and separated by 4% to 12% NuPAGE Bis-Tris gel (Life Technologies) and transferred to polyvinylidene difluoride membrane (Bio-Rad Laboratories, Hercules, CA). The membrane was incubated with primary antibodies overnight at 4°C, followed by incubation with the corresponding horseradish peroxidase--conjugated secondary antibody \[Research Resource Identifier (RRID): AB_772209; RRID: AB_772206; GE Health Care Life Sciences, Pittsburgh, PA\] at room temperature for 1 hour. The Western blots were visualized using Thermo Scientific ECL Plus reagent (Thermo Scientific Inc., Pittsburgh, PA). Densitometric analysis was performed using LabImage 4.1 (Bio-Rad Laboratories). The primary antibodies used included anti-cleaved caspase 3 (RRID: AB_2070042), anti-caspase 3 (RRID: AB_2069872), anti-cleaved poly(ADP-ribose) polymerase (PARP) (RRID: AB_2160592), and anti-ubiquitin (RRID: AB_2180538) (Cell Signaling Technology), and anti--*β*-tubulin (RRID: AB_1844090) (Sigma-Aldrich).

RNA extraction and real-time quantitative polymerase chain reaction {#s6}
-------------------------------------------------------------------

Messenger RNA (mRNA) was extracted using the RNAQuick-micro kit (Zymo Research, Irvine, CA). mRNA was quantified by Nanodrop (Thermo Scientific Inc.), and 1 µg was reverse transcribed with the SuperScript III RT kit (Life Technologies), according to the manufacturer's instructions. Quantitative polymerase chain reaction was performed in ABI Viia-7 (Life Technologies) using TaqMan probes for *Snail1*, *Snail2*, *Twist1*, *Nanog*, *Epo*, and *Vegfa* (Life Technologies). The amount of mRNA detected was normalized to control *Actb* mRNA values. Relative gene expression was calculated as a percentage of the value obtained in nontreated animals from the same experiment.

Animal experiments and bioluminescence imaging {#s7}
----------------------------------------------

All animal studies were conducted in accordance with the principles and procedures outlined in the National Institutes of Health *Guide for the Care and Use of Animals* and approved by the National Institutes of Health Animal Care and Use Committee. A total of 1.5 × 10^6^ MTT-Luc cells was injected subcutaneously in the right lower dorsal side of female athymic nude mice (Charles River, Germantown, MD). The experimental groups consisted of 6-week-old mice housed in a pathogen-free facility. After 10 days, allowing for tumor cells to engraft, we started intraperitoneal injection with bortezomib (1 mg/kg; n = 10), salinosporamid A (0.075 mg/kg; n = 10), or the combination (0.25 mg/kg + 0.025 mg/kg salinosporamid A; n = 10) twice per week for 28 days. Each group also had control animals treated with vehicle (n = 10 per experiment). The animals were imaged weekly by bioluminescence. All bioluminescent data were collected with a Xenogen IVIS system (STTARR, Toronto, ON, Canada). For *in vivo* imaging, luciferase activity was assessed in anesthetized animals 10 minutes after intraperitoneal administration of 150 mg/kg luciferin (VivoGlo; Promega, Fitchburg, WI) in phosphate-buffered saline. The experiments were performed in the National Institutes of Health Mouse Image Facility in accordance with Animal Care and Use Committee regulations. All imaging variables were equal, and photographic and bioluminescent images at different time points were collected for each sample.

Immunofluorescence staining and analysis {#s8}
----------------------------------------

The tumors from the animals were embedded in paraffin, and slides with 5-µm--thick tissue recuts were prepared. The tissue was deparaffinized and rehydrated prior to antigen retrieval in citrate sodium buffer (pH 6.0) for 20 minutes. The sections were incubated with primary antibody for 1 hour at room temperature, followed by 1-hour incubation with secondary antibody labeled with DyLight 594 (RRID: AB_2336413) (Vector Laboratories, Burlingame, CA). The nuclei were labeled with NucBlue Live ReadyProbes Reagent (Life Technologies) for 10 minutes and mounted with Mowiol mounting solution (Millipore, Billerica, MA). The staining was analyzed by fluorescence microscopy. The primary antibodies used included anti-Ki67 (RRID: AB_443209), anti-CD31 (RRID: AB_726362) (Abcam, Cambridge, UK), and cleaved caspase 3 (RRID: AB_2070042) (Cell Signaling Technology). All immunofluorescence staining was acquired by a Zeiss AxioObserver Z1 microscope fitted with an automated scanning stage, Colibri II LED illumination, and Zeiss ZEN software using a high-resolution AxioCam MRm camera and a 20× objective. Each fluorophore channel was pseudo-colored in ZEN2 (Zeiss, Oberkochen, Germany), exported as TIFF, and analyzed using the FIJI distribution of ImageJ ([@B20]). Vessel length and density were measured from CD31-stained images. Vessel length was measured from stitched image covering the entire section. Vessel density corresponds to the percentage of the field stained for CD31. The proliferation index and cleaved caspase 3 ratio were determined by automatic counting of cell nuclei and positive staining. The ratio (positive signal/nuclei) was calculated in Excel (Microsoft, Redmond, WA). At least six images were used from each of the five tumors (per group) analyzed.

Statistical analyses {#s9}
--------------------

Statistical analyses were performed using GraphPad Prism software to calculate the nonparametric Mann--Whitney *U* test (GraphPad Software, San Diego, CA).

Results {#s10}
=======

Bortezomib and salinosporamid A exhibit cytotoxic effect on mouse PHEO cells {#s11}
----------------------------------------------------------------------------

To investigate the possible use of bortezomib and salinosporamid A in PHEO therapy, we first evaluated the cytotoxic effect of these compounds on mouse PHEO cells *in vitro*. MPC and MTT cells were treated with bortezomib, salinosporamid A, or their combination. After 48 hours of incubation, the LD~50~ was 7.3 nM and 6.3 nM for bortezomib and 107.2 nM and 42.43 nM for salinosporamid A in MPC and MTT cells, respectively, demonstrating a higher sensitivity of these cells to bortezomib than salinosporamid A \[[Fig. 1(a)](#F1){ref-type="fig"}\]. To evaluate the cytotoxic effect of the bortezomib and salinosporamid A combination, MPC and MTT cells were treated with the concentrations described in [Fig. 1(b)](#F1){ref-type="fig"}. The addition of 10 nM salinosporamid A to both 10 nM and 100 nM bortezomib resulted in a significantly reduced number of viable MPC (*P* = 0.0015 and *P* = 0.0390, respectively) and MTT (*P* = 0.0197 and *P* \< 0.0001, respectively) cells than when the same concentration of bortezomib was used alone, suggesting an additive effect on PHEO cells \[[Fig. 1(b)](#F1){ref-type="fig"}\].

![Bortezomib alone and in combination with salinosporamid A exhibits cytotoxic effect on PHEO cells and inhibits their migration and invasion. (a) MPC and MTT cells were treated with the indicated concentrations of bortezomib or salinosporamid A for 48 hours. Cell viability was assessed by methylthiazolyldiphenyl-tetrazolium bromide assay. The box and whiskers graphs represent data from three independent experiments. (b) MPC and MTT cells were treated with the indicated concentrations of bortezomib, salinosporamid A, or their combination for 48 hours. Cell viability was assessed by methylthiazolyldiphenyl-tetrazolium bromide assay. The box and whiskers graphs represent data from three independent experiments. (c) A total of 1.5 × 10^5^ MPC was plated in the upper part of Transwell chambers and allowed to migrate for 24 hours in the presence of bortezomib, salinosporamid A, or their combination. In the case of invasion, matrigel-coated Transwell chambers were used. The box and whiskers graph represents data from three independent experiments. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001, Mann--Whitney *U* test. B, 1 nM bortezomib; S, 10 nM salinosporamid A.](en.2017-00592f1){#F1}

Bortezomib and salinosporamid A decrease PHEO cell migration and invasion {#s12}
-------------------------------------------------------------------------

Because migration and invasion are key processes in carcinogenesis, especially in metastasis development, we next evaluated the effect of the two proteasome inhibitors on migratory abilities of the cells. We treated MPC with bortezomib, salinosporamid A, and both in combination at sublethal doses. Although there was not a significant difference in migration of the cells treated with salinosporamid A, we observed a significantly decreased number of migrated cells treated with bortezomib when compared with control cells (*P* = 0.0043) \[[Fig. 1(c)](#F1){ref-type="fig"}\]. The combination of bortezomib and salinosporamid A further inhibited cell migration (*P* = 0.0022). Similarly, bortezomib significantly inhibited invasion of MPC (*P* \< 0.0001), and this inhibition was magnified in combination with salinosporamid A (*P* \< 0.0001). Salinosporamid A did not significantly affect invasion of the cells when used as a single treatment. No cytotoxicity was observed at any of these drug concentrations. These results suggest that bortezomib alone or in combination with salinosporamid A is an effective inhibitor of migration and invasion of PHEO cells and might exhibit antimetastatic properties *in vivo.*

Bortezomib and salinosporamid A exert their cytotoxic effect via apoptosis in PHEO cells *in vitro* {#s13}
---------------------------------------------------------------------------------------------------

The ability of proteasome inhibitors to induce cell death via apoptosis has been well established ([@B4]). To investigate whether these drugs exhibited their cytotoxic effect via the same mechanism in PHEO cells, we treated MPC and MTT cells with bortezomib or salinosporamid A for 24 hours. As hypothesized, the treatments led to accumulation of ubiquitinated proteins in the PHEO cells. Although in bortezomib-treated cells the elevated level of ubiquitinated proteins was seen at 10 nM, a similar effect in cells treated with salinosporamid A was not observed until 100 nM \[[Fig. 2(a)](#F2){ref-type="fig"}\]. We also detected increased levels of the apoptotic markers cleaved caspase 3 and cleaved PARP in treated cells. Again, a 10-fold lower concentration of bortezomib was sufficient to induce a similar effect to the one seen in cells treated with 100 nM salinosporamid A. Based on the observed additive effect of the bortezomib and salinosporamid A combination, we treated MPC and MTT cells with 100 nM bortezomib, 100 nM salinosporamid A, and combinations of the two for 0, 8, 16, and 24 hours. The strongest induction of apoptosis was seen in cells treated with bortezomib alone at all time points, beginning at 8 hours. However, after 24 hours, the difference in the levels of cleaved caspase 3 and cleaved PARP between 100 nM bortezomib alone and the combination of 5 nM bortezomib and 10 nM salinosporamid A was less striking. At all time points, treatment with salinosporamid A alone induced the apoptotic pathway to the least extent \[[Fig. 2(b)](#F2){ref-type="fig"}\]. These results suggest that bortezomib and salinosporamid A induce cell death through apoptosis and that 10 times lower concentrations of each compound in the combination are sufficient to produce a similar outcome.

![Bortezomib and salinosporamid A activate apoptosis in PHEO cells. (a) MPC and MTT cells were treated with bortezomib or salinosporamid A, at concentrations of 0, 1, 10, 100, and 1000 nM for 24 hours. Total cell lysates were subjected to Western blot with antibodies against ubiquitin, cleaved PARP, cleaved caspase 3, and caspase 3. *β*-tubulin was used as a loading control. A representative image (n = 3) is shown. (b) MPC were treated with 100 nM bortezomib, 100 nM salinosporamid A, or their combination. Time course analysis of cleaved PARP, cleaved caspase 3, and caspase 3 in total cell lysates was performed. *β*-tubulin was used as a loading control. A representative image (n = 3) is shown. \*, 10 nM salinosporamid A + 5 nM bortezomib; +, 10 nM salinosporamid A + 10 nM bortezomib; B, 100 nM bortezomib; S, 100 nM salinosporamid A.](en.2017-00592f2){#F2}

Combined bortezomib and salinosporamid A inhibits tumor growth of mouse PHEO {#s14}
----------------------------------------------------------------------------

To test the effect of bortezomib and salinosporamid A *in vivo*, we divided the animals into three groups and treated them with bortezomib, salinosporamid A, or a combination of the two. After 21 days of treatment, we observed a significant inhibition of tumor growth in the animals treated with bortezomib alone (*P* = 0.0036) and the combination (*P* = 0.0371). The growth remained delayed until the end of the study at 28 days (*P* = 0.0068, *P* = 0.0209, respectively). The tumors were also significantly smaller in the treated groups after 28 days of treatment \[[Fig. 3(a) and 3(b)](#F3){ref-type="fig"}\]. We did not observe tumor growth inhibition in animals treated only with salinosporamid A.

![Bortezomib alone and in combination with salinosporamid A inhibits tumor growth and decreases expression levels of angiogenesis and stem cell markers *in vivo.* (a) Nude female mice bearing MTT-Luc tumors were treated with bortezomib, salinosporamid A, or a combination for 28 days. The control group was treated with vehicle. Tumor sizes were assessed once per week. The graph shows tumor growth in the groups treated with bortezomib alone (red), salinosporamid A (green), or the combination (purple) compared with control (black) animals. The graph represents data from treated and control mice assessed at specific time points as mean ± standard error of the mean. Statistical analysis was performed by Mann--Whitney *U* test, at each time point. (b) Tumors removed from the treated and control mice after 28 days of treatment. Scale bar: 1 cm. (c) mRNA expression levels of *Vegfa*, *Epo*, *Nanog*, *Snail1*, *Snail2*, and *Twist1* in tumors from treated and control groups were assessed by quantitative real-time polymerase chain reaction. The target gene transcript levels were normalized to *Actb*. The box and whiskers graphs represent data from control (n = 15) and treated (each group n = 5) animals. (d) Total proteins were extracted from tumors from groups treated with bortezomib, salinosporamid A, their combination, and control animals, and were subjected to Western blot with antibodies against ubiquitin, cleaved caspase 3, and caspase 3. *β*-tubulin was used as a loading control. \**P* \< 0.05; \*\* *P* \< 0.01; \*\*\**P* \< 0.001, Mann--Whitney *U* test. B, 1 mg/kg bortezomib; B + S, combination of 0.25 mg/kg bortezomib and 0.025 mg/kg salinosporamid A; C, control; *Epo*, erythropoietin; *Nanog*, Nanog homeobox; S, 0.075 mg/kg salinosporamid A; *Snail1*, snail family zinc finger 1; *Snail2*, snail family zinc finger 2; *Vegfa*, vascular endothelial growth factor A.](en.2017-00592f3){#F3}

Based on our *in vitro* results showing the inhibitory effect of the compounds on cell migration and invasion of MPC, we evaluated the gene expression of epithelial--mesenchymal transition (EMT), stem cell, and proangiogenic markers in the tumors. The expression levels of *Snail1*, *Snail2*, and *Twist1* were not significantly modified in any of the treatment groups when compared with control animals. In contrast, the expression levels of the proangiogenic factor *Epo* were significantly decreased in the animals treated with either individual drug or their combination \[[Fig. 3(c)](#F3){ref-type="fig"}\]. Compared with controls, the *P* values were 0.0355, 0.0019, and 0.0002 for the bortezomib group, salinosporamid A group, and the combination group, respectively. *Vegfa* expression levels were significantly lower only in the group treated with the combination (*P* = 0.0011). In addition, we detected significantly lower expression of the stem cell marker *Nanog* in the bortezomib (*P* = 0.0262)- and combination (*P* = 0.0004)-treated groups \[[Fig. 3(c)](#F3){ref-type="fig"}\].

To assess the mechanism of action of the drugs in the allograft mouse models, sections were taken from control and treated tumors and stained for proliferation (Ki67), angiogenesis (CD31), and apoptosis (cleaved caspase 3) markers. When compared with the control mice, proliferation was significantly inhibited in tumors treated with bortezomib and the combination (*P* = 0.0016, *P* \< 0.0001, respectively), whereas no significant effect was observed in tumors treated with salinosporamid A alone ([Fig. 4](#F4){ref-type="fig"}). Because angiogenesis is a key feature of tumorigenesis involved in nutrient supply and metastasis formation, we stained the tumors for CD31. Although we did not observe any difference in the density of blood vessels in the tumors, we did detect significantly reduced vessel length and diameter in the tumors treated with bortezomib and the combination (*P* \< 0.001 in all cases). Interestingly, we also observed reduced vascularity in the animals treated only with salinosporamid A (*P* \< 0.001) ([Fig. 4](#F4){ref-type="fig"}). Increased levels of cleaved caspase 3 in tumors treated with bortezomib and the combination confirmed the proapoptotic effect of the proteasome inhibitors on PHEOs in mice \[[Figs. 3(d) and 4](#F3){ref-type="fig"}[](#F4){ref-type="fig"}\]. We also detected accumulation of ubiquitinated proteins in these tumors, validating the efficient proteasome inhibition *in vivo* \[[Fig. 3(d)](#F3){ref-type="fig"}\]. Again, no difference in the ubiquitin profile was observed in the animals treated with salinosporamid A, even though a significant increase in cleaved caspase 3--positive cells was seen (*P* \< 0.01) ([Fig. 4](#F4){ref-type="fig"}).

![Bortezomib alone and in combination with salinosporamid A decreases tumor cell proliferation and angiogenesis and increases apoptotic cell death *in vivo.* (a) Representative images of Ki-67 staining (left), CD31 staining (middle), and cleaved caspase 3 (right) in control and treated groups (n = 5 for all groups). Proteins of interest are colored red; blue represents 4′,6-diamidino-2-phenylindole staining. Magnification: ×20. Scale bar: 50 μm. (b) Box and whiskers graphs showing the proliferation index, vessel diameter, vessel length, and cleaved caspase 3--positive cells, respectively. Each graph contains data from control and treated animals (n = 5 for all groups). \*\**P* \< 0.01; \*\*\**P* \< 0.001, Mann--Whitney *U* test. B, 1 mg/kg bortezomib; B + S, combination of 0.25 mg/kg bortezomib and 0.025 mg/kg salinosporamid A; C, control; S: 0.075 mg/kg salinosporamid A.](en.2017-00592f4){#F4}

The results obtained *in vivo* suggest that bortezomib alone or in combination with salinosporamid A might be a potential candidate for treatment of PHEO/PGL, as the compounds inhibit tumor cell proliferation and angiogenesis and induce cell death. In contrast, salinosporamid A is unlikely to be effective alone and may have utility only as a part of combination therapy with other proteasome inhibitors (including bortezomib) and/or other regimens and compounds used in anticancer therapies to increase the efficacy of the treatment and/or reduce the toxicity.

Discussion {#s15}
==========

In the current study, we evaluated the effects of the proteasome inhibitors bortezomib and salinosporamid A in PHEO cell models *in vitro* and *in vivo*. We have shown that the cytotoxic effect of the drugs is exerted mainly via apoptosis induction. We also observed that bortezomib alone and in combination with salinosporamid A inhibited migration and invasion of MPC *in vitro* and reduced proliferation of PHEO cancer cells and angiogenesis *in vivo.*

Despite extensive ongoing research, metastatic PHEO/PGL remains a devastating disease with no curative treatment options besides surgery. Although the CVD chemotherapy combination has proven to be effective in some patients, its efficacy is frequently limited by the acquisition of resistance by cancer cells ([@B13]). Therefore, there is a need to identify effective drugs that could be used to defeat the disease or delay the occurrence of metastases after surgery. Proteasome inhibitors are emerging therapeutic compounds for various types of aggressive and highly resistant cancers ([@B21], [@B22]). They exert their activity by affecting several processes, including cell cycle, apoptosis, cell signaling, and transcription ([@B3]).

We decided to further investigate effects of bortezomib because the compound was previously part of a high-throughput screening study performed by our group, in which it was ranked as one of the most potent drugs to induce PHEO cell death ([@B14]). We confirmed the results in our study, in which bortezomib exerted its cytotoxicity via induction of the apoptotic pathway. This pathway is very frequently activated, either p53 dependently or independently, by this drug ([@B5]). Even though bortezomib is a very effective treatment of hematologic malignancies, it is also associated with numerous limitations, including off-target effects and short-term proteasomal inhibition ([@B9]). In initial studies, bortezomib exhibited a very high efficacy in several types of cancer cell lines; however, it has since been shown that bortezomib as a single agent is not as effective in treatment of solid tumors as it was first assumed ([@B7], [@B23], [@B24]). In contrast, salinosporamid A, which binds to all three catalytic 20S subunits irreversibly, is able to inhibit proteasome activity for a longer period of time and therefore is hypothesized to be more potent than bortezomib ([@B8]). In fact, salinosporamid A has been shown to be effective in bortezomib-refractory multiple myelomas and is in clinical trials for several types of solid tumors. In addition, fewer side effects have been associated with salinosporamid A treatment ([@B9]). It has also been reported that salinosporamid A induces apoptosis more rapidly and sustains proteasome inhibition longer than bortezomib ([@B25]). However, we did not observe the same results in MPC/MTT cell models, in which 10-fold higher concentrations of salinosporamid A than of bortezomib were necessary to activate apoptosis to a comparable extent. Similarly, when the two drugs were used at sublethal doses individually, only bortezomib had an inhibitory effect on migration and invasion of the PHEO cells. Although a study performed by Baritaki *et al.* ([@B26]) described inhibition of EMT in prostate cancer cells treated with salinosporamid A via a mechanism involving inhibition of Snail and NF-*κ*B, our *in vivo* study found no significant decrease in the expression of *Snail1*, *Snail2*, and *Twist1* in tumors treated with this compound alone.

To overcome resistance development and reduce side effects of treatment, regimens affecting either the same target via slightly different mechanisms or two or more different targets are very frequently combined. Both bortezomib and salinosporamid A have been used in combination with each other, with radio- or chemotherapy, or with other compounds, showing promising results ([@B27]--[@B30]). We combined bortezomib with salinosporamid A to decrease the bortezomib concentrations needed for treatment. In *in vitro* experiments, we showed that a combination of bortezomib and salinosporamid A activated apoptosis to a comparable level seen at a 10 times higher concentration of bortezomib alone after 24 hours. A similar effect was exhibited on EMT properties of MPC, as the combination inhibited their migration and invasion more effectively than bortezomib alone. We also observed an additive effect of the drugs in inducing death of PHEO cells, confirming previous reports demonstrating the potential of proteasome inhibitor combinations as an applicable therapeutic approach for cancer treatment ([@B27], [@B31]).

Our *in vivo* results are partially in accordance with the findings of Chauhan *et al.* ([@B27]), who first reported that the combination of lower doses of salinosporamid A and bortezomib inhibited tumor growth, whereas higher doses of the drugs administered individually did not. Although in their study using multiple myeloma cells neither of the two compounds exhibited a significant effect on tumor growth individually, our study found that bortezomib alone and in combination with salinosporamid A showed a similar inhibitory effect on tumor growth. In contrast, with salinosporamid A alone, no significant inhibition was observed. These results are suggestive of cell line specificity, off-target effects of bortezomib, and a different mechanism of action for inducing extended cell death independently of proteasome inhibition when compared with salinosporamid A, which has been previously reported ([@B8]). However, although the effect on tumor growth was comparable in both (bortezomib-treated and combination-treated) experimental groups, proliferation was more reduced in the tumors treated with the combination than bortezomib alone, suggesting an additive antiproliferative effect of these two drugs. It was interesting to observe that angiogenesis was inhibited in all treated animals, regardless if bortezomib, salinosporamid A, or the combination was used.

Depending on the situation, NF-*κ*B exhibits either proapoptotic or antiapoptotic activity, and the NF-*κ*B pathway is deregulated in numerous types of cancer ([@B32]). Although we have not evaluated inhibition of NF-*κ*B signaling in this study, the results of Pacak *et al.* ([@B33]) showed that NF-*κ*B inhibitors induce apoptosis in PHEO cells *in vitro* and *in vivo*. NF-*κ*B suppression is thought to be the primary mechanism of action of bortezomib, as well as other proteasome inhibitors ([@B22], [@B23]). Proteasome inhibition suppresses NF-*κ*B transcriptional activity and can thus sensitize the cells to apoptosis and regulate metastases formation and angiogenesis via downregulation of numerous target genes, including *VEGF* ([@B34]--[@B36]). These mechanisms were also induced by both bortezomib and salinosporamid A in PHEO cells, which suggests a prospective application of proteasome inhibitors in PHEO/PGL treatment. Bortezomib as a single agent did not show any objective response, and no remission was observed in a Phase II clinical trial in patients with metastatic carcinoids and islet cell tumors, which are also neuroendocrine tumors ([@B37]). In contrast, several reports have shown its antitumor and antiangiogenic effect on chemosensitive as well as chemoresistant neuroblastoma cell lines *in vitro* and *in vivo*, either alone or in combination with other drugs ([@B38]--[@B41]). It has also been included in Phase I/II of clinical trials for treatment of neuroblastoma, in which the compound is combined with a topoisomerase I inhibitor (Irinotecan), histone deacetylase inhibitor (SAHA), or an ornithine decarboxylase inhibitor ([@B29], [@B42], [@B43]). Neuroblastomas and PHEO/PGL are tumors of neuroendocrine origin, sharing numerous features. In fact, a cluster analysis performed by Szabó *et al.* ([@B44]) showed that neuroblastoma and PHEO/PGL share more similarities than any other tumors compared in the study. Despite the differences between these two types of neuroendocrine tumors, the promising findings in neuroblastoma treatment increase the probability of its efficacy also in PHEO/PGL therapy. In addition, in our previous studies, we obtained promising results using the topoisomerase I inhibitor LMP-400 and SAHA in PHEO cells in *vitro* and *in vivo* ([@B14], [@B15]). Other groups also reported successful application of proteasome inhibitors in combination with heat-shock protein 90 inhibitors, which proved to be effective in PHEO cells as well ([@B17]). CVD chemotherapy is administered to patients with metastatic PHEO/PGL ([@B13]), and bortezomib has been used in combination with cyclophosphamide in several clinical trials for different types of blood cancer ([@B45]--[@B48]), suggesting the addition of bortezomib to CVD treatment might be beneficial for PHEO/PGL patients. Moreover, an increase in the stability of subunit B of succinate dehydrogenase (SDHB) via regulation of protein homeostasis represents a promising approach to rescue the function of the succinate dehydrogenase complex in PHEO/PGL ([@B49]). PHEOs/PGLs caused by mutations in *SDHB* represent the biggest challenge in the treatment of the disease, as they frequently progress toward metastatic disease. Disruption of succinate dehydrogenase function leads to a number of carcinogenesis-related processes, including increased reactive oxygen species generation and accumulation of succinate, which promotes pseudohypoxia ([@B49]). It was shown that the quantitative loss of otherwise functional mutant SDHB protein is caused by elevated ubiquitin binding and consequent proteasomal degradation. Yang *et al.* ([@B49]) showed that treatment with compounds modulating protein stability and proteostasis, including histone deacetylase inhibitors, resulted in slower degradation and decreased mutant SDHB protein ubiquitination. These results support further investigation of proteasome inhibitors as future treatment options for PHEO/PGL patients, especially in combination studies.

In summary, we have shown the efficacy of bortezomib and its combination with salinosporamid A in PHEO models *in vitro* and *in vivo*. The compounds induce cell death via apoptosis, decrease PHEO cell migration and invasion, and inhibit tumor growth and cell proliferation. These findings propose that proteasome inhibitors be further investigated for their possible application in the treatment of PHEO/PGL patients. The fact that bortezomib is a Food and Drug Administration--approved drug and several other proteasome inhibitors are being tested in clinical trials makes these compounds a very attractive therapeutic option to be used either individually or, preferably, in combination with other regimens.

Abbreviations: CVDcyclophosphamide, vincristine, and dacarbazineEMTepithelial--mesenchymal transitionMPCmouse pheochromocytoma cellmRNAmessenger RNAMTTmouse tumor tissueNF-*κ*Bnuclear factor-*κ*BPARPpoly(ADP-ribose) polymerasePHEO/PGLpheochromocytoma/paragangliomaRRIDResearch Resource IdentifierSDHBsuccinate dehydrogenase complex iron sulfur subunit B.
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###### 

**Antibody Table**

  **Peptide/Protein Target**   **Antigen Sequence (if Known)**   **Name of Antibody**                                                               **Manufacturer, Catalog No.**          **Species Raised in; Monoclonal or Polyclonal**   **Dilution Used**        **RRID**
  ---------------------------- --------------------------------- ---------------------------------------------------------------------------------- -------------------------------------- ------------------------------------------------- ------------------------ ------------
  Cleaved caspase 3                                              Cleaved caspase-3 (Asp175) (5A1E) rabbit mAb                                       Cell Signaling, 9664                   Rabbit; monoclonal                                WB: 1:1,000; IF: 1:400   AB_2070042
  Caspase 3                                                      Caspase-3 (8G10) rabbit mAb                                                        Cell Signaling, 9665                   Rabbit; monoclonal                                1:1,000                  AB_2069872
  Cleaved PARP                                                   Cleaved PARP (Asp214) (7C9) mouse mAb (mouse specific)                             Cell Signaling, 9548                   Mouse; monoclonal                                 1:1,000                  AB_2160592
  *β*-Tubulin                                                    Monoclonal anti--*β*-tubulin, clone AA2                                            Sigma-Aldrich, T8328                   Mouse; monoclonal                                 1:1,000                  AB_1844090
  Ubiquitin                                                      Ubiquitin antibody                                                                 Cell Signaling, 3933                   Rabbit; polyclonal                                1:1,000                  AB_2180538
  ki67                                                           Anti-Ki67 antibody                                                                 Abcam, ab15580                         Rabbit; polyclonal                                1:2,000                  AB_443209
  CD31                                                           Anti-CD31 antibody                                                                 Abcam, ab28364                         Rabbit; polyclonal                                1:50                     AB_726362
  Anti-mouse                                                     Anti-mouse IgG, peroxidase-linked species-specific whole antibody (from sheep)     GE Health Care Life Sciences, NXA931   Sheep; polyclonal                                 1:30,000                 AB_772209
  Anti-rabbit                                                    Anti-rabbit IgG, peroxidase-linked species-specific whole antibody (from donkey)   GE Health Care Life Sciences, NA934    Donkey; polyclonal                                1:30,000                 AB_772206
  Anti-rabbit 594                                                DyLight 594 goat anti-rabbit IgG antibody                                          Vector Laboratories, DI-1594           Goat; polyclonal                                  1:1,000                  AB_2336413

Abbreviations: IF, immunofluorescence; IgG, immunoglobulin G; mAb, monoclonal antibody; WB, Western blot.
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